Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer

This study investigated the incidence of cardiac dysfunction in patients with advanced or recurrent epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer treated with EGFR- tyrosine kinase inhibitors.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Non-Small Cell Lung Cancer (MeSH Term: Carcinoma, Non-Small-Cell Lung) Bronchial Neoplasms Carcinoma, Bronchogenic Carcinoma, Non-Small-Cell Lung Cardiotoxicity Cardiovascular Diseases Chemically-Induced Disorders Drug-Related Side Effects and Adverse Reactions Drug-Related Side Effects and Adverse Reactions (MeSH Term) Egfr Tyrosine Kinase Inhibitor Heart Diseases Lung Diseases Lung Neoplasms Neoplasms Neoplasms by Site Pathologic Processes Pathological Conditions, Signs and Symptoms Radiation Injuries Respiratory Tract Diseases Respiratory Tract Neoplasms Thoracic Neoplasms Wounds and Injuries

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Taichung Veterans General Hospital

Taichung, 407, Taiwan

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

patients with advanced or recurrent EGFR-mutant NSCLC receiving EGFR-TKI treatment

Exclusion criteria

Treatment and study plan

EGFR-TKI

Drug

Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line.

EGFR tyrosine kinase inhibitor

Other

Erlotinib, dacomitinib, afatinib, and osimertinib, with dose according to NCCN guide line

Primary outcomes

The incidence of cancer therapy-related cardiac dysfunction after treatment with EGFR tyrosine kinase inhibitors.

Time frame: From enrollment to 2 years after initiating EGFR tyrosine kinase inhibitor treatment.

Cancer therapy-related cardiac dysfunction was defined as a left ventricular ejection fraction of less than 50% and an absolute reduction in LVEF of more than 10% from baseline.

Sponsors and collaborators

Lead sponsor

Taichung Veterans General Hospital

Other

Registry information

Official study title

Cancer Therapy-Related Cardiac Dysfunction Associated With EGFR-TKIs in Advanced EGFR-mutant Non-small Cell Lung Cancer: A Single-center Prospective Observational Study

Important dates

Study start: 2022
Primary completion: 2024
Study completion: 2024
First posted: Dec 5, 2025
Registry last updated: Dec 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting